Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Advertisement
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Getting the right care team, treatment, and testing are three steps to empower patients with MM.
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
A study described several mutations and subclone events that appear to drive relapse in multiple myeloma.
Research suggests that "targeting FcRH5 with CAR T cells may represent a promising therapeutic avenue for MM.”
Researchers identified 1,055 patients diagnosed with MM from 2004 to 2018 who underwent AHSCT within a year of diagnosis.
Researchers conducted interviews to gather the perspectives of both clinicians and nurses.
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
The panel discusses optimal dosing for teclistamab.
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.